Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, is pleased to announce the formation of a Scientific Advisory Board.
This expert board will provide scientific guidance and valuable market insights, primarily focusing on addressing emerging trends such as the integration of blood-based biomarkers, the collaborative possibilities for computerised cognitive assessments, and the benefits of diverse populations and patient meaningfulness for clinical trials. It will also review and advise on product strategies, scientific approaches, and evidence-generation for regulatory and data strategies.